Drugs / OTC
OTC drug warning letters: CGMP themes to watch
Recent public warning letters show the same lesson for OTC drug makers: FDA does not treat marketing, manufacturing, laboratory controls, and quality oversight as separate stories.
What showed up in the source documents
Two May 2026 letters in the digest sample cite OTC finished pharmaceuticals and CGMP concerns. The useful pattern is not a single violation label. It is the way FDA connects product claims, manufacturing control, testing, and the quality unit.
- Process validation and repeatable manufacturing controls matter before a product scales.
- Laboratory controls need evidence, not loose sign-off.
- Quality-unit oversight becomes a visible issue when the public record shows gaps.
Why it matters for monitoring
A warning letter can become a content source for consultants, quality teams, and operators because it shows public examples of what FDA is willing to put in writing.